19 completed, 9 terminated, 4 recruiting, 3 unknown. 37 Phase 1, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 37 | Completed 19, Terminated 9, Recruiting 4, Unknown 3, Active not recruiting 1, Suspended 1 |
| Phase 2 | 12 | Completed 7, Terminated 5 |
Follow Peritoneal Cancer: new trials by email Literature Review of Peritoneal Cancer trials Research Report on Peritoneal Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors vvDD-hIL-2-RG-1 - Gastric Neoplasms, Esophageal Cancer | Phase 1 | Recruiting | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | 18 | 2025-05-06 | 2025-06-03 |
| Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors BL-M17D1 - Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer | Phase 1 | Terminated | SystImmune Inc. | 3 | 2025-04-10 | 2026-09-22 |
| MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer FT538, Enoblituzumab - Cancer, Solid Tumor | Phase 1 | Terminated | Masonic Cancer Center, University of Minnesota | 1 | 2023-04-28 | 2025-08-14 |
| A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer KAND567, Carboplatin - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 1 / Phase 2 | Completed | Novakand Pharma AB | 18 | 2023-04-26 | 2025-06-08 |
| A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy Allocetra-OTS, Nivolumab, Tislelizumab - Solid Tumor, Peritoneal Metastases | Phase 1 / Phase 2 | Terminated | Enlivex Therapeutics RDO Ltd. | 14 | 2022-11-15 | 2024-04-17 |
| Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer Microdevice - Ovarian Cancer, Fallopian Tube Cancer | Phase 1 | Recruiting | Brigham and Women's Hospital | 20 | 2022-11-01 | 2026-05-18 |
| BP1001-A in Patients With Advanced or Recurrent Solid Tumors BP1001-A (Liposomal Grb2 Antisense Oligonucleotide), BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel - Solid Tumor, Adult, Carcinoma, Ovarian Epithelial | Phase 1 | Recruiting | Bio-Path Holdings, Inc. | 50 | 2022-08-19 | 2025-03-07 |
| A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) ELU001 - Ovarian Cancer, Ovarian Neoplasms | Phase 1 / Phase 2 | Terminated | Elucida Oncology | 79 | 2021-09-13 | 2024-08-07 |
| T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer Ipilimumab, Cyclophosphamid, Fludarabine Phosphate - Metastatic Ovarian Cancer, Metastatic Fallopian Tube Cancer | Phase 1 / Phase 2 | Terminated | Inge Marie Svane | 6 | 2021-04-22 | 2025-08-12 |
| A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer Azenosertib, Carboplatin, Pegylated liposomal doxorubicin - Solid Tumor, Epithelial Ovarian Cancer | Phase 1 | Recruiting | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 172 | 2020-10-26 | 2026-04-07 |
| Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors Bosutinib, Pemetrexed - Carcinoma, Non-Small-Cell Lung, Mesothelioma | Phase 1 | Completed | Nagla Abdel Karim | 6 | 2019-12-10 | 2022-06-14 |
| Phase I Trial HIPEC With Nal-irinotecan nanoliposomal irinotecan - Peritoneal Cancer, Pseudomyxoma Peritonei | Phase 1 | Completed | Stony Brook University | 18 | 2019-10-22 | 2022-05-06 |
| Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer Carboplatin, Paclitaxel, Pembrolizumab - Ovarian Cancer Stage IV, Peritoneal Cancer | Phase 1 / Phase 2 | Completed | The Netherlands Cancer Institute | 33 | 2017-11-01 | 2024-05-29 |
| Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer entinostat, avelumab, Placebo - Epithelial Ovarian Cancer, Peritoneal Cancer | Phase 1 / Phase 2 | Completed | Syndax Pharmaceuticals | 140 | 2016-12-19 | 2024-01-10 |
| Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer niraparib, pembrolizumab - Neoplasms, Triple Negative Breast Cancer | Phase 1 / Phase 2 | Completed | Tesaro, Inc. | 122 | 2016-04-15 | 2022-12-01 |
| Study of Prolanta™ in Recurrent or Persistent Epithelial Ovarian Cancer Prolanta, a human prolactin receptor antagonist - Ovarian Cancer, Peritoneal Cancer | Phase 1 | Unknown | Oncolix, Inc. | 18 | 2016-02-01 | 2018-02-14 |
| Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies COTI2, Cisplatin - Ovarian Cancer, Fallopian Tube Cancer | Phase 1 | Unknown | Critical Outcome Technologies Inc. | 51 | 2015-12-01 | 2019-02-01 |
| Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer DPX-Survivac, DPX-Survivac(Aqueous), Cyclophosphamide - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 1 | Completed | ImmunoVaccine Technologies, Inc. (IMV Inc.) | 37 | 2013-08-23 | 2021-06-18 |
| A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer MEK162, MEK inhibitor; oral, Paclitaxel, mitotic inhibitor; intravenous - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 1 | Completed | Array Biopharma, now a wholly owned subsidiary of Pfizer | 36 | 2012-07-01 | 2020-09-14 |
| Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer E39 peptide (100mcg)/GM-CSF vaccine plus E39 booster, Non-vaccine clinically matched control group, E39 peptide (500mcg)/GM-CSF vaccine plus E39 booster - Ovarian Cancer, Endometrial Cancer | Phase 1 / Phase 2 | Completed | COL George Peoples, MD, FACS | 51 | 2012-04-01 | 2020-05-04 |
Showing 20 of 37. Sign in to see all of them.
Fallopian Tube Neoplasms (28) · Ovarian Neoplasms (28) · Carcinoma, Ovarian Epithelial (7) · Endometrial Neoplasms (7) · Uterine Cervical Neoplasms (4) · Breast Neoplasms (3) · Neoplasms (3) · Recurrence (3) · Stomach Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Mesothelioma (2) · Ovarian Diseases (2) · Adenocarcinoma, Mucinous (1) · Carcinoma (1)
Neoplasms by Site (34) · Adnexal Diseases (32) · Endocrine Gland Neoplasms (32) · Endocrine System Diseases (32) · Female Urogenital Diseases (32) · Female Urogenital Diseases and Pregnancy Complications (32) · Genital Diseases (32) · Genital Diseases, Female (32) · Genital Neoplasms, Female (32) · Gonadal Disorders (32) · Urogenital Diseases (32) · Urogenital Neoplasms (32) · Neoplasms (31) · Ovarian Diseases (30) · Fallopian Tube Diseases (28)
Carboplatin (7) · Paclitaxel (7) · Bevacizumab (3) · Cyclophosphamide (3) · Cisplatin (2) · Gemcitabine (2) · Nivolumab (2) · pembrolizumab (2) · 10-propargyl-10-deazaaminopterin (1) · Alemtuzumab (1) · Antimitotic Agents (1) · Chemokine CX3CL1 (1) · Dasatinib (1) · Docetaxel (1) · Folic Acid (1)
Dana-Farber Cancer Institute (2) · ImmunoVaccine Technologies, Inc. (IMV Inc.) (2) · M.D. Anderson Cancer Center (2) · Massachusetts General Hospital (2) · AA Secord (1) · Abramson Cancer Center at Penn Medicine (1) · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) (1) · Array Biopharma, now a wholly owned subsidiary of Pfizer (1) · Bio-Path Holdings, Inc. (1) · Brigham and Women's Hospital (1) · COL George Peoples, MD, FACS (1) · Critical Outcome Technologies Inc. (1) · Elucida Oncology (1) · Enlivex Therapeutics RDO Ltd. (1) · Genentech, Inc. (1)
United States (32) · Canada (4) · Denmark (2) · Israel (2) · Spain (2) · Australia (1) · Bosnia and Herzegovina (1) · Bulgaria (1) · Georgia (1) · Netherlands (1) · Norway (1) · Serbia (1) · South Korea (1) · Sweden (1) · United Kingdom (1)
Amit Oza (1) · Angeles A Secord, MD (1) · Apostolia Tsimberidou, MD, PhD (1) · Eileen H. Shinn, PhD (1) · Elizabeth Stover, MD, PhD (1) · George Coukos, M.D., Ph.D. (1) · Georgios Georgakis, MD (1) · Hanna Dahlstrand, MD/PhD (1) · Inge Marie Svane, Prof., M.D. (1) · John C Elkas, MD, JD (1) · Joseph Kim, MD (1) · Kristin Zorn, MD (1) · Marcela G. del Carmen, MD, MPH (1)
PMID 26119093, PMID 26405584, PMID 29799676, PMID 31194225, PMID 31194228, PMID 31685558, PMID 32193378, PMID 33119478, PMID 35397664, PMID 36410913, PMID 36482193
2019 (1), K07CA093512 (1), P01CA111412 (1), R21CA216796 (1)